Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Stock Rated "Hold" by Wall Street Brokerages

Key Points

• Analyst consensus is “Hold”: Two analysts recommend selling and three recommend buying, with an average 12-month price target of $38.67. Recent ratings included buy targets of $37 and $38, alongside sell and strong-sell downgrades.
• Institutional interest increased: MAC Alpha Capital Management acquired 2.15 million shares worth approximately $29.8 million, representing about 3.03% of Pharming Group.
• Shares rose 6.3% but fundamentals remain mixed: PHAR opened at $11.90, well below its 52-week high of $21.34, while the company’s latest quarterly EPS of $0.02 missed the $0.06 consensus estimate.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) has been assigned an average recommendation of "Hold" from the five research firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $38.67.

A number of research firms recently weighed in on PHAR. Wall Street Zen raised shares of Pharming Group to a "hold" rating in a report on Saturday. Weiss Ratings reiterated a "sell (d)" rating on shares of Pharming Group in a report on Friday, August 7th. HC Wainwright reissued a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a report on Tuesday, September 22nd. Canaccord Genuity Group set a $38.00 price target on shares of Pharming Group in a research report on Wednesday, September 23rd. Finally, Zacks Research downgraded Pharming Group from a "hold" rating to a "strong sell" rating in a research note on Friday, July 31st.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP purchased a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,148,144 shares of the company's stock, valued at approximately $29,838,000. Pharming Group makes up approximately 6.0% of MAC Alpha Capital Management LP's holdings, making the stock its 2nd largest position. MAC Alpha Capital Management LP owned approximately 3.03% of Pharming Group as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 0.03% of the company's stock.

Pharming Group Stock Up 6.3%

Shares of NASDAQ:PHAR opened at $11.90 on Tuesday. Pharming Group has a 1 year low of $9.11 and a 1 year high of $21.34. The stock has a 50-day simple moving average of $10.69 and a 200-day simple moving average of $13.92. The stock has a market capitalization of $842.28 million, a P/E ratio of 99.17 and a beta of -0.05. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.31 and a current ratio of 3.01.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. Equities analysts forecast that Pharming Group will post 0.32 earnings per share for the current year.

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming's principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.